The repurposed anthelmintic mebendazole in combination with trametinib suppresses refractory NRAS(Q61K) melanoma

Structure-based drug repositioning in addition to random chemical screening is now a viable route to rapid drug development. Proteochemometric computational methods coupled with kinase assays showed that mebendazole (MBZ) binds and inhibits kinases important in cancer, especially both BRAF(WT) and B...

Descripción completa

Detalles Bibliográficos
Autores principales: Simbulan-Rosenthal, Cynthia M., Dakshanamurthy, Sivanesan, Gaur, Anirudh, Chen, You-Shin, Fang, Hong-Bin, Abdussamad, Maryam, Zhou, Hengbo, Zapas, John, Calvert, Valerie, Petricoin, Emanuel F., Atkins, Michael B., Byers, Stephen W., Rosenthal, Dean S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Priority Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5355037/
https://www.ncbi.nlm.nih.gov/pubmed/28157711
http://dx.doi.org/10.18632/oncotarget.14990

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5355037/
https://www.ncbi.nlm.nih.gov/pubmed/28157711
http://dx.doi.org/10.18632/oncotarget.14990

Ejemplares similares